ESPE Abstracts

Background: Type 1 diabetes is associated with deficits in skeletal muscle and bone mass and quality. Inhibition of myostatin, a negative regulator of muscle mass, was explored as a therapeutic modality to improve the muscle and bone phenotype associated with insulin-deficient diabetes.Methods: We investigated whether an inhibitory myostatin antibody in streptozotocin (STZ)-induced diabetes in female mice is protective f...